These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9406716

  • 1. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
    Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J.
    Cancer; 1997 Dec 15; 80(12 Suppl):2618-23. PubMed ID: 9406716
    [Abstract] [Full Text] [Related]

  • 2. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar 15; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.
    J Nucl Med; 1998 Nov 15; 39(11):1937-43. PubMed ID: 9829586
    [Abstract] [Full Text] [Related]

  • 5. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [Abstract] [Full Text] [Related]

  • 6. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    J Nucl Med; 1999 Jan 15; 40(1):198-204. PubMed ID: 9935077
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.
    J Nucl Med; 1998 Sep 15; 39(9):1608-13. PubMed ID: 9744353
    [Abstract] [Full Text] [Related]

  • 9. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2002 Sep 15; 13(5):1054-70. PubMed ID: 12236788
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [Abstract] [Full Text] [Related]

  • 11. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques.
    Devys A, Thedrez P, Gautherot E, Faivre-Chauvet A, Saï-Maurel C, Rouvier E, Auget JL, Barbet J, Chatal JF.
    Int J Cancer; 1996 Sep 17; 67(6):883-91. PubMed ID: 8824563
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
    Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM.
    Nat Med; 2005 Nov 17; 11(11):1250-5. PubMed ID: 16258537
    [Abstract] [Full Text] [Related]

  • 14. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, Supiot S, Barbet J, Chatal JF, Thédrez P.
    Mol Cancer Ther; 2002 Feb 17; 1(4):267-74. PubMed ID: 12467222
    [Abstract] [Full Text] [Related]

  • 15. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
    Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardiès M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3190s-3198s. PubMed ID: 10541363
    [Abstract] [Full Text] [Related]

  • 17. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.
    Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF.
    J Nucl Med; 1999 Jul 01; 40(7):1216-21. PubMed ID: 10405144
    [Abstract] [Full Text] [Related]

  • 18. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
    Hillairet De Boisferon M, Raguin O, Thiercelin C, Dussaillant M, Rostène W, Barbet J, Pélegrin A, Gruaz-Guyon A.
    Bioconjug Chem; 2002 Jul 01; 13(3):654-62. PubMed ID: 12009958
    [Abstract] [Full Text] [Related]

  • 19. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.
    Cancer Res; 1997 Dec 01; 57(23):5309-19. PubMed ID: 9393755
    [Abstract] [Full Text] [Related]

  • 20. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.